Opendata, web and dolomites

EASIVIRAL SIGNED

EASIVIRAL

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EASIVIRAL project word cloud

Explore the words cloud of the EASIVIRAL project. It provides you a very rough idea of what is the project "EASIVIRAL" about.

granted    pcr    portable    market    labs    robustness    portfolio    30    hiv    1b    rt    life    manufacturing    critical    ebitda    76    improvements    techniques    operated    offers    displace    diagnoses    2016    therapy    altratech    blood    elimination    18m    biotechnologies    hepatitis    people    received    decades    poc    viral    structure    commercialise    intervention    crisis    clinical    laboratories    feasibility    jobs    grow    2024    gt    combination    seal    stated    accuracy    210m    detection    capacity    easiviral    detect    diagnostics    battery    simultaneous    disruptive    time    excellence    local    region    load    september    patient    refrigerated    kit    care    alone    patents    revenues    successful    accelerated    prescription    format    virus    proven    threshold    vl    innovative    exceeded    combo    urges    portability    point    sme    trl    75    biomarkers    cumulative    enhances    centered    outcomes    competitiveness    viruses    create    acceptance    ceo    clinics    share    spread    disrupt    capture    saving    significantly    12    ltd    stops    phc    innovations    see    2015    made    reagents    partners    supply    exists    purify    venture    mins    solution   

Project "EASIVIRAL" data sheet

The following table provides information about the project.

Coordinator
ALTRATECH LIMITED 

Organization address
address: 4TH FLOOR 103/104 O CONNELL STREET
city: LIMERICK
postcode: V94 AT85
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.easiviral.com
 Total cost 2˙969˙000 €
 EC max contribution 2˙969˙000 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2020-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ALTRATECH LIMITED IE (LIMERICK) coordinator 2˙969˙000.00

Map

 Project objective

In September 2016 WHO-Europe stated “Europe is at a critical point with HIV. New diagnoses in the European Region recently increased by 76%”. WHO urges “an accelerated people-centered response” based on taking HIV viral-load (VL) testing out of labs and into local clinics where it is most needed at point-of-care (PoC). No such solution exists today. New disruptive innovations are needed to address this. AltraTech Ltd has developed three proven biotechnologies to capture, purify, and detect the HIV virus from a blood sample, in 40 mins, using proven HIV biomarkers. This enables life-saving clinical intervention, immediate prescription and therapy for the patient, and stops further spread of the virus. The three techniques are innovative. Their combination, in a portable battery-operated kit format, is disruptive. It offers the unique combination of portability, robustness, reduced cost, with simultaneous increase in accuracy, combo-detection of Hepatitis and other viruses, and elimination of refrigerated reagents. It will address the above crisis, the HIV-VL PoC market, and has the potential to disrupt the €1B viral clinical diagnostics market and displace RT-PCR diagnostics that have been used in laboratories for two decades. Following a successful SME-Phase-1 feasibility, the technology received a Seal-of-Excellence in Phase-2(PHC-12-2015) – exceeded funding threshold. TRL improvements have been made in 2016, and a new CEO, management structure, and new venture funding significantly enhances AltraTech capacity to commercialise EASIVIRAL and see it reach market acceptance. The outcomes will enable capture a market leading share of > 30% of the €210M PoC HIV-VL market, reach cumulative EBITDA for this product alone of more than €18M by 2024. AltraTech will create 75 new jobs during this time, grow its portfolio of granted patents on its disruptive EASIVIRAL technology, and increase the revenues, jobs, and competitiveness of its manufacturing supply partners

 Deliverables

List of deliverables.
1000 fabricated silicon sensor chips Demonstrators, pilots, prototypes 2020-02-12 16:28:30
Poster showing lower-limit of quantification Websites, patent fillings, videos etc. 2020-02-12 16:28:31
Data Sheets, App Notes, White Papers, Publicity material Websites, patent fillings, videos etc. 2020-01-30 10:06:41

Take a look to the deliverables list in detail:  detailed list of EASIVIRAL deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EASIVIRAL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EASIVIRAL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More